TARA
NASDAQ HealthcareProtara Therapeutics, Inc. - Common Stock
Biotechnology
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.
๐ Market Data
| Price | $5.32 |
|---|---|
| Volume | 394,905 |
| Market Cap | 292.92M |
| Beta | 1.500 |
| RSI (14-Day) | 58.1 |
| 200-Day MA | $5.03 |
| 50-Day MA | $5.44 |
| 52-Week High | $7.82 |
| 52-Week Low | $2.77 |
| Forward P/E | -3.83 |
| Price / Book | 1.45 |
๐ฏ Investment Strategy Scores
TARA scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Moon Shot (78/100) โ this strategy High growth potential (high beta + oversold).
Lowest fit among scored strategies: ๐ Institutional Whale (6/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find TARA in your text
Paste any article, transcript, or post โ the tool will extract TARA and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.